Bio-Matrix Scientific Group, Inc. Announces It Will Open Two DNA-Genetic Testing Labs

Main Category: Genetics
Also Included In: Stem Cell Research
Article Date: 03 Apr 2008 - 5:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Bio-Matrix Scientific Group Inc (OTCBB: BMSN), a biotechnology company focused on adult stem cell processing and cryogenic storage, announced it will open two DNA-Genetic Testing laboratories for the molecular-level detection of genes linked to specific human diseases.

With approximately 2,000 disease associated genes identified, and over 4,000 diseases caused by genetic defects, genetic testing used to assess the risk of developing certain diseases will become an increasingly important part of medical practice.

Dr. Geoffrey O'Neill, the Company's Chief Scientific Advisor, noted "Development of DNA testing capability complements our stem cell preservation programs. Possible disease associations at the DNA level for diseases such as diabetes or Alzheimer's would certainly be a strong incentive for our clients to store their stem cells for future regenerative medical procedures."

Bio-Matrix currently has two Class 100,000 DNA laboratories that will be utilized to reduce the risks of contamination during DNA amplification and testing. These laboratories, combined with our current cGMP/cGTP requirements as an FDA registered Facility for stem cell operations, will assure clients of the highest standards in all technologies used.

About Bio-Matrix Scientific Group

Bio-Matrix Scientific Group Inc. is a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market. The company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation. Bio-Matrix' new 15,000 sq. ft. state-of-the-art facility, located in the heart of San Diego's biotechnology corridor, will house Bio-Matrix' two secure Cryogenic Stem Cell Bank, three research laboratories, aseptic cellular/tissue class 10,000/100 processing laboratory, hematology, microbiology and flow cytometry laboratories.

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Bio-Matrix Scientific Group